{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:37Z","timestamp":1791355777618,"version":"4.3.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peanut oral immunotherapy (pOIT) can achieve desensitization, yet patients with high peanut-sIgE may experience more adverse reactions and treatment failure. We evaluated a conservative pOIT protocol in children with high Ara h 2-sIgE (\u226540\u2005kU\/L) and examined longitudinal basophil activation test (BAT) and sIgE\/sIgG4 trajectories as candidate biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-two peanut-allergic children underwent pOIT, including 16 with high and 16 with lower Ara h 2-sIgE. All received low-dose initiation and slow up-dosing. Clinical outcomes, safety, and immunologic markers were evaluated longitudinally for up to 36 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Effective desensitization (\u2265300\u2005mg peanut protein) was achieved in 68.8% of high-sIgE and 62.5% of lower-sIgE participants. One severe adverse event occurred in each subgroup, with no treatment-related discontinuations. Peanut and Ara h 2\/6-sIgE levels rose transiently before gradually declining, whereas sIgG4 increased early, leading to a reduced sIgE\/sIgG4 ratio. A ratio &amp;lt;50 was associated with effective desensitization. BAT responses initially increased and subsequently declined, with progressive increase in the activation threshold. Baseline BAT and sIgE were not associated with desensitization. However, BAT area under the curve (AUC) &amp;lt;100 was significantly associated with effective desensitization with ROC AUC of 0.784 (bootstrap 95% CI 0.536\u20130.983). Exploratory time-lagged analyses did not establish prospective predictive utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Low-dose initiation, slow-escalation pOIT achieved effective desensitization in patients with high Ara h 2-sIgE, without treatment-related discontinuations. Longitudinal reductions in BAT and sIgE\/sIgG4 ratio were associated with increased ingested dose. These exploratory biomarkers may provide adjunctive information during pOIT, but prospective validation is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1902025","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:51Z","timestamp":1791352251000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal basophil activation testing for assessing response to low-dose initiation, slow-escalation peanut oral immunotherapy in patients with high Ara h 2-sIgE"],"prefix":"10.3389","volume":"7","author":[{"given":"Jinguo","family":"Chen","sequence":"first","affiliation":[{"name":"Virant Diagnostics Laboratory","place":["Wheaton, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Joanna","family":"Yu","sequence":"additional","affiliation":[{"name":"Virant Diagnostics Laboratory","place":["Wheaton, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Institute for Asthma and Allergy (IAA)","place":["Chevy Chase, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wan","sequence":"additional","affiliation":[{"name":"Virant Diagnostics Laboratory","place":["Wheaton, MD, United States"]},{"name":"Institute for Asthma and Allergy (IAA)","place":["Chevy Chase, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Chiao","sequence":"additional","affiliation":[{"name":"Virant Diagnostics Laboratory","place":["Wheaton, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Economides","sequence":"additional","affiliation":[{"name":"Institute for Asthma and Allergy (IAA)","place":["Chevy Chase, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingfen","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Johns Hopkins University","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Henry","family":"Li","sequence":"additional","affiliation":[{"name":"Virant Diagnostics Laboratory","place":["Wheaton, MD, United States"]},{"name":"Institute for Asthma and Allergy (IAA)","place":["Chevy Chase, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/all.16404","article-title":"Efficacy and safety of dupilumab in children with peanut allergy: a multicenter, open-label, phase II study","volume":"80","author":"Sindher","year":"2025","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaip.2013.12.006","article-title":"Predicting outcomes of oral food challenges by using the allergen-specific IgE-total IgE ratio","volume":"2","author":"Gupta","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","year":"2024"},{"key":"B4","doi-asserted-by":"publisher","first-page":"100747","DOI":"10.1016\/j.waojou.2023.100747","article-title":"Oral immunotherapy for food allergy: translation from studies to clinical practice?","volume":"16","author":"Pouessel","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/all.16345","article-title":"EAACI guidelines on the management of IgE-mediated food allergy","volume":"80","author":"Santos","year":"2025","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1111\/all.15211","article-title":"Allergen immunotherapy and\/or biologicals for IgE-mediated food allergy: a systematic review and meta-analysis","volume":"77","author":"de Silva","year":"2022","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(21)02390-4","article-title":"Efficacy and safety of oral immunotherapy in children aged 1\u20133 years with peanut allergy (the immune tolerance network IMPACT trial): a randomised placebo-controlled study","volume":"399","author":"Jones","year":"2022","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13223-025-00948-5","article-title":"Food oral immunotherapy","volume":"20","author":"McHenry","year":"2024","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","article-title":"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study","volume":"394","author":"Chinthrajah","year":"2019","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1111\/all.16262","article-title":"Two-year post-treatment outcomes following peanut oral immunotherapy in the probiotic and peanut oral immunotherapy-003 long-term (PPOIT-003LT) study","volume":"79","author":"Loke","year":"2024","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaip.2017.05.006","article-title":"Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy","volume":"6","author":"Baumert","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.anai.2020.03.028","article-title":"Quality of life improves significantly after real-world oral immunotherapy for children with peanut allergy","volume":"125","author":"Blackman","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaip.2018.10.048","article-title":"Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy","volume":"7","author":"Blumchen","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/pai.12898","article-title":"Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan","volume":"29","author":"Nagakura","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.aller.2017.05.002","article-title":"Oral immunotherapy for food allergy: a Spanish guideline. Egg and milk immunotherapy Spanish guide (ITEMS GUIDE). part 2: maintenance phase of cow milk (CM) and egg oral immunotherapy (OIT), special treatment dosing schedules. Models of dosing schedules of OIT with CM and EGG","volume":"45","author":"Martorell","year":"2017","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaci.2020.03.026","article-title":"Ara h 2 is the dominant peanut allergen despite similarities with ara h 6","volume":"146","author":"Hemmings","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1321863","DOI":"10.3389\/fimmu.2024.1321863","article-title":"Low-dose oral immunotherapy in immunoglobulin E-mediated food allergies","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.3390\/ijms26083535","article-title":"Allergen immunotherapy: pitfalls, perks and unexpected allies","volume":"26","author":"Tamas","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3390\/cells14090639","article-title":"Role of IgG4 antibodies in human health and disease","volume":"14","author":"Shi","year":"2025","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaip.2023.11.027","article-title":"Mechanisms and predictive biomarkers of allergen immunotherapy in the clinic","volume":"12","author":"Layhadi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1080\/1744666X.2024.2336568","article-title":"Basophil activation test in the food allergy clinic: its current use and future applications","volume":"20","author":"Bergmann","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jaci.2019.10.038","article-title":"Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE","volume":"145","author":"Tsai","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1111\/all.14752","article-title":"A novel approach to the basophil activation test for characterizing peanut allergic patients in the clinical setting","volume":"76","author":"Agyemang","year":"2021","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s40629-015-0074-0","article-title":"Guidelines on the management of IgE-mediated food allergies: s2k-guidelines of the German society for allergology and clinical immunology (DGAKI) in collaboration with the German medical association of allergologists (AeDA), the German professional association of pediatricians (BVKJ), the German allergy and asthma association (DAAB), German dermatological society (DDG), the German society for nutrition (DGE), the German society for gastroenterology, digestive and metabolic diseases (DGVS), the German society for oto-rhino-laryngology, head and neck surgery, the German society for pediatric and adolescent medicine (DGKJ), the German society for pediatric allergology and environmental medicine (GPA), the German society for pneumology (DGP), the German society for pediatric gastroenterology and nutrition (GPGE), German contact allergy group (DKG), the Austrian society for allergology and immunology (AE-GAI), German professional association of nutritional sciences (VDOE) and the association of the scientific medical societies Germany (AWMF)","volume":"24","author":"Worm","year":"2015","journal-title":"Allergo J Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100876","DOI":"10.1016\/j.waojou.2024.100876","article-title":"Updated grading system for systemic allergic reactions: joint statement of the world allergy organization anaphylaxis committee and allergen immunotherapy committee","volume":"17","author":"Turner","year":"2024","journal-title":"World Allergy Organ J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.jaci.2021.12.789","article-title":"Updating the CoFAR grading scale for systemic allergic reactions in food allergy","volume":"149","author":"Chinthrajah","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1133378","DOI":"10.3389\/falgy.2023.1133378","article-title":"Towards standardizing basophil identification by flow cytometry","volume":"4","author":"Sonder","year":"2023","journal-title":"Front Allergy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","article-title":"SRplot: a free online platform for data visualization and graphing","volume":"18","author":"Tang","year":"2023","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1613237","DOI":"10.3389\/falgy.2025.1613237","article-title":"The safety and efficacy of oral immunotherapy compared to epicutaneous immunotherapy in peanut allergen desensitisation amongst the paediatric cohort-a narrative review","volume":"6","author":"Chowdhury","year":"2025","journal-title":"Front Allergy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1016\/j.jaip.2024.09.007","article-title":"A streamlined strategy for basophil activation testing in a multicenter phase III clinical trial","volume":"12","author":"Su\u00e1rez-Fari\u00f1as","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/all.13138","article-title":"Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI position paper","volume":"72","author":"Shamji","year":"2017","journal-title":"Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/nu18081252","article-title":"Peanut oral immunotherapy in children: an Italian single-center retrospective cohort study","volume":"18","author":"Pessina","year":"2026","journal-title":"Nutrients"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jaci.2024.02.017","article-title":"Neutralizing IgG(4) antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy","volume":"153","author":"Keswani","year":"2024","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1902025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:52Z","timestamp":1791352252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1902025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":34,"alternative-id":["10.3389\/falgy.2026.1902025"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1902025","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1902025"}}